Aethlon Medical reported fiscal first quarter results for the period ended June 30, 2026. The company raised approximately $4.0 million in gross proceeds through a public offering of common stock subsequent to the quarter-end. Cash and cash equivalents stood at approximately $4.9 million as of June 30, 2026. Operating expenses decreased 11.9% to approximately $1.6 million compared to $1.8 million in the prior-year period. Clinically, the company dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia and had a Long COVID manuscript accepted for publication. Aethlon Medical is a clinical-stage medical therapeutic company developing the Hemopurifier, an investigational extracorporeal immunotherapeutic platform designed to remove tumor-derived extracellular vesicles and enveloped viruses from circulation.

Aethlon Medical, Inc. filed a Certificate of Change with the Nevada Secretary of State on July 30, 2026, authorizing a one-for-five reverse stock split of its common stock. The transaction becomes effective at 10:00 a.m. Eastern Time on July 31, 2026, with split-adjusted trading expected to commence on August 4, 2026. The company stated the move supports capital markets strategy and compliance with Nasdaq Listing Rule 5550(a)(2). Authorized shares will decrease from 100 million to 20 million, reducing outstanding shares from approximately 3.25 million to roughly 649,914. Fractional shares are rounded up to whole shares rather than paid out in cash. Aethlon Medical, Inc. operates in the medical device industry, specializing in extracorporeal blood purification technologies.

Aethlon Medical, Inc. entered into a Securities Purchase Agreement on July 6, 2026, to conduct a registered public offering. The company issued 263,000 shares of common stock, 5,633,009 common warrants, and 5,370,009 pre-funded warrants at a combined price of $0.71 per unit. The offering closed on July 7, 2026, generating approximately $4.0 million in gross proceeds and approximately $3.335 million in net proceeds after paying Maxim Group LLC a 6.25% cash fee and expense reimbursements. Net proceeds are intended for general working capital. Aethlon Medical, Inc. is a medical technology company.

Aethlon Medical, Inc. issued a press release on June 10, 2026, regarding its financial results for the quarter ended March 31, 2026. The company is in the medical technology industry and develops specialized medical devices and therapeutics.